Skip to main content

Table 2 Univariate analysis of survival-related characteristics in platinum-sensitive recurrent ovarian cancer

From: Secondary cytoreduction surgery improves prognosis in platinum-sensitive recurrent ovarian cancer

Variable TTP (OR 95% CI) OS (OR 95% CI)
FIGO stage
I 1.00(reference) 1.00(reference)
II 1.25(0.57–4.31) 1.44(0.66–4.45)
III 3.09(1.53–8.36) 3.71(2.34–8.95)
IV 4.64(2.85–12.26) 4.96(2.51–11.14)
Grade
Low 1.00(reference) 1.00(reference)
High 5.22(2.14–12.76) 4.02(1.95–10.33)
Ascites
No 1.00(reference) 1.00(reference)
Yes 1.78(1.44–2.38) 1.94(1.48–2.27)
Optimal initial CRS
Yes 1.00(reference) 1.00(reference)
No 6.07(2.50–15.91) 6.84(3.32–13.86)
Optimal secondary CRS
Yes 1.00(reference) 1.00(reference)
No 5.28(1.86–16.93) 9.30(4.29–19.51)
Neo-chemotherapy
Yes 1.00(reference) 1.00(reference)
No 1.19(1.04–1.57) 1.45(0.79–2.75)
Paclitaxel-based chemotherapy
Yes 1.00(reference) 1.00(reference)
No 1.02(0.85–1.39) 1.35(0.83–2.01)
PFS 1.02(1.00–1.18) 1.13(1.07–1.30)
Nadir CA-125 1.02(1.00–1.03) 1.03(1.00–1.06)
  1. CRS cytoreduction surgery; OS overall survival; TTP time to progression; PFS progression-free survival.